Sutimlimab is a monoclonal antibody targeting complement subunit C1s, used to reduce the need for blood transfusions in patients with cold agglutinin disease (CAD) due to hemolysis; it selectively inhibits the classical complement pathway by targeting C1s, thereby preventing complement-mediated red blood cell destruction.